Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. IDXX
IDXX logo

IDXX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy IDEXX Laboratories Inc (IDXX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
561.890
1 Day change
0.86%
52 Week Range
769.980
Analysis Updated At
2026/03/27
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

IDEXX Laboratories Inc (IDXX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown strong financial performance in its latest quarter, the technical indicators and options data suggest a neutral to bearish sentiment in the short term. Additionally, analysts have lowered price targets, and there are no recent positive news catalysts or significant insider or congressional trading activity to support an immediate buy decision.

Technical Analysis

The stock's MACD is below zero and negatively contracting, indicating bearish momentum. RSI is neutral at 34.592, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 580.079, with key support at 565.707 and resistance at 594.451. Overall, technical indicators suggest a bearish trend.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

The high Option Volume Put-Call Ratio of 4.38 indicates bearish sentiment, with significantly more puts traded than calls. Implied volatility is at 36.78, with an IV percentile of 74.9, suggesting elevated uncertainty.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
9
Buy
2

Positive Catalysts

  • Hedge funds are significantly increasing their positions in the stock, with a 764.05% increase in buying activity over the last quarter. The company's financials for Q4 2025 showed strong growth in revenue (14.28% YoY), net income (14.82% YoY), and EPS (17.56% YoY).

Neutral/Negative Catalysts

  • Analysts have lowered price targets, citing concerns about muted Q1 growth, macroeconomic headwinds, and slower margin expansion. No recent news or congressional trading data is available to provide additional support for the stock. Technical indicators and options data suggest bearish sentiment.

Financial Performance

In Q4 2025, IDEXX Laboratories reported revenue of $1.09 billion, up 14.28% YoY. Net income increased to $248.19 million, up 14.82% YoY, and EPS rose to 3.08, up 17.56% YoY. Gross margin improved slightly to 60.35%, up 0.92% YoY. The company demonstrated strong financial growth in the latest quarter.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst ratings have been mixed to slightly negative. Piper Sandler, Barclays, UBS, and BTIG all lowered their price targets, citing concerns about muted growth, macro headwinds, and a softer margin outlook. However, Barclays and BTIG maintain an Overweight and Buy rating, respectively, while others remain Neutral.

Wall Street analysts forecast IDXX stock price to rise
10 Analyst Rating
Wall Street analysts forecast IDXX stock price to rise
7 Buy
3 Hold
0 Sell
Moderate Buy
Current: 557.090
sliders
Low
750
Averages
792.78
High
850
Current: 557.090
sliders
Low
750
Averages
792.78
High
850
Stifel
Jonathan Block
Buy
downgrade
$775 -> $675
AI Analysis
2026-03-31
New
Reason
Stifel
Jonathan Block
Price Target
$775 -> $675
AI Analysis
2026-03-31
New
downgrade
Buy
Reason
Stifel analyst Jonathan Block lowered the firm's price target on Idexx Laboratories to $675 from $775 and keeps a Buy rating on the shares. The firm continues to view Idexx as more of a second half story, the analyst tells investors.
Piper Sandler
Neutral
downgrade
$775 -> $750
2026-02-09
Reason
Piper Sandler
Price Target
$775 -> $750
2026-02-09
downgrade
Neutral
Reason
Piper Sandler lowered the firm's price target on Idexx Laboratories to $750 from $775 and keeps a Neutral rating on the shares following quarterly results. The firm says its updated price target primarily reflects its updated multiple and rolling forward of estimates to 2027 from 2026.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for IDXX
Unlock Now

People Also Watch